In support of our data, neuroblastoma is the third most sensitive among 25 different cancer lineages that are sensitive to knockdown of KDM6B but not KDM6A (Supplementary Fig. 3a, b), just below prostate cancer and myeloma, in a genome-wide shRNA screen (20 shRNAs per gene) in 709 cancer cell lines (DepMap dataset). This evidence concerns the gene KDM6A and prostate carcinoma.